Genmab's HuMax-CD4 Displays Unique Mechanism of Action

Genmab A/S has announced the discovery of unique mechanisms of action of HuMax-CD4, currently in development for treatment of cutaneous T-cell lymphoma and non-cutaneous T-cell lymphoma.

In experimental laboratory models and studies in human patients, HuMax-CD4 eliminated CD4 positive T-cells by combining rapid signaling inhibition with efficient engagement of immune system killer cells.

The signaling in CD4 positive target cells is inhibited through a combination of both potent inhibition of signaling via the T cell receptor, and the activation of different signaling proteins that can effectively stop cell signaling processes. Blockade of cell signaling is a key feature for effective antibody therapeutics for cancer.

CD4 positive T-cells are also attacked by immune effector cells via an immune defense mechanism called antibody-dependent cell-mediated cytotoxicity (ADCC). HuMax-CD4, furthermore, induces the down-modulation of CD4 targets from target cell surfaces via a slow immune cell-mediated mechanism.

- These exciting data document the way HuMax-CD4 works to kill target cells and highlights its potential for the treatment of cancer, said Prof. Jan G.J. van de Winkel, Chief Scientific Officer of Genmab.

The data will be published today (15 October) in an article in the journal Cancer Research.

Source: Genmab, press release, 15.10.07